American Renal Associates Holdings Inc (ARA) Receives $13.89 Average Price Target from Analysts

Shares of American Renal Associates Holdings Inc (NYSE:ARA) have earned an average recommendation of “Hold” from the ten research firms that are presently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and one has issued a buy rating on the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $13.89.

ARA has been the topic of a number of recent analyst reports. Zacks Investment Research cut American Renal Associates from a “buy” rating to a “hold” rating in a report on Friday, January 25th. Barclays set a $9.00 target price on shares of American Renal Associates and gave the stock a “hold” rating in a research note on Thursday, March 28th. SunTrust Banks downgraded shares of American Renal Associates from a “buy” rating to a “hold” rating and set a $10.46 price target for the company. in a research report on Monday, March 11th. ValuEngine cut shares of American Renal Associates from a “sell” rating to a “strong sell” rating in a research note on Monday, March 11th. Finally, Svb Leerink cut shares of American Renal Associates from an “outperform” rating to a “market perform” rating in a research note on Monday, March 11th.

A number of hedge funds have recently added to or reduced their stakes in the business. Foresters Investment Management Company Inc. purchased a new stake in shares of American Renal Associates during the 4th quarter valued at $3,822,000. Dimensional Fund Advisors LP grew its position in American Renal Associates by 39.2% in the 3rd quarter. Dimensional Fund Advisors LP now owns 690,103 shares of the company’s stock worth $14,941,000 after purchasing an additional 194,395 shares during the last quarter. BlackRock Inc. lifted its stake in shares of American Renal Associates by 17.1% in the 3rd quarter. BlackRock Inc. now owns 955,892 shares of the company’s stock worth $20,693,000 after acquiring an additional 139,789 shares during the period. Federated Investors Inc. PA lifted its stake in shares of American Renal Associates by 72.0% in the 1st quarter. Federated Investors Inc. PA now owns 266,231 shares of the company’s stock worth $1,635,000 after acquiring an additional 111,470 shares during the period. Finally, Altrinsic Global Advisors LLC lifted its stake in American Renal Associates by 83.3% during the first quarter. Altrinsic Global Advisors LLC now owns 220,000 shares of the company’s stock valued at $1,351,000 after purchasing an additional 100,000 shares during the last quarter. 93.96% of the stock is owned by hedge funds and other institutional investors.

Shares of ARA stock traded up $0.02 on Wednesday, hitting $6.74. The company had a trading volume of 132,257 shares, compared to its average volume of 213,961. The stock has a market cap of $217.86 million, a PE ratio of 9.57 and a beta of 2.08. The company has a quick ratio of 1.00, a current ratio of 1.03 and a debt-to-equity ratio of 5.48. American Renal Associates has a twelve month low of $5.48 and a twelve month high of $23.99.

American Renal Associates Company Profile

American Renal Associates Holdings, Inc operates as a dialysis services provider in the United States. It operates dialysis clinics focusing on joint venture partnerships with physicians. The company offers kidney dialysis services to patients suffering from chronic kidney failure or end stage renal disease.

See Also: New Google Finance Tool and Screening Stocks

Analyst Recommendations for American Renal Associates (NYSE:ARA)

Receive News & Ratings for American Renal Associates Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for American Renal Associates and related companies with MarketBeat.com's FREE daily email newsletter.